Peter Nash
Impact in
- Rheumatology top 0.02%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
- Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 248
- Rheumatoid Arthritis Research and Therapies 151
- Spondyloarthritis Studies and Treatments 144
- Systemic Lupus Erythematosus Research 30
- Immunology 89
- Psoriasis: Treatment and Pathogenesis 70
- Biosimilars and Bioanalytical Methods 10
- Co-authors
- Dafna D. Gladman (36 shared papers)Daniel O. Clegg (2 shared papers)Philip Mease (7 shared papers)Christian Antoni (1 shared paper)Philip J. Mease (66 shared papers)Désirée van der Heijde (15 shared papers)Luminita Pricop (37 shared papers)Iain B. McInnes (46 shared papers)
- Journals
- Annals of the Rheumatic Diseases (90 papers)Rheumatology and Therapy (22 papers)Lara D. Veeken (21 papers)RMD Open (13 papers)The Journal of Rheumatology (12 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Peter Nash
340 papers receiving 11.6k citations
Peter Nash's Hit Papers
Peers
Comparison fields: 5 of 138
- Rheumatology 7.1k
- Hematology 2.0k
- Immunology 3.5k
- Pathology and Forensic Medicine 1.3k
- Dermatology 635
Countries citing papers authored by Peter Nash
This map shows the geographic impact of Peter Nash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Nash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Nash more than expected).
Fields of papers citing papers by Peter Nash
This network shows the impact of papers produced by Peter Nash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Nash. The network helps show where Peter Nash may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Nash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 345 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Psoriatic arthritis: epidemiology, clinical features, course, and outcome Hit paper breakdown → | 2005 | 1225 |
| 2 | Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis Hit paper breakdown → | 2015 | 593 |
| 3 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Hit paper breakdown → | 2004 | 528 |
| 4 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 462 |
| 5 | Treatment recommendations for psoriatic arthritis Hit paper breakdown → | 2008 | 428 |
| 6 | 2009 | 349 | |
| 7 | 2004 | 326 | |
| 8 | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials Hit paper breakdown → | 2017 | 312 |
| 9 | 2010 | 295 | |
| 10 | 2013 | 275 | |
| 11 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update Hit paper breakdown → | 2015 | 257 |
| 12 | 2004 | 254 | |
| 13 | 2008 | 252 | |
| 14 | A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial Hit paper breakdown → | 2019 | 216 |
| 15 | Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial Hit paper breakdown → | 2020 | 184 |
| 16 | Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial Hit paper breakdown → | 2021 | 173 |
| 17 | 2011 | 158 | |
| 18 | 2012 | 141 | |
| 19 | 2020 | 140 | |
| 20 | 2004 | 138 |
About Peter Nash
Peter Nash is a scholar working on Rheumatology, Immunology, Hematology, Pathology and Forensic Medicine and Genetics, having authored 345 papers that have together received 12.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (151 papers), Spondyloarthritis Studies and Treatments (144 papers), Psoriasis: Treatment and Pathogenesis (70 papers), Autoimmune and Inflammatory Disorders Research (55 papers), Systemic Lupus Erythematosus Research (30 papers), Chronic Lymphocytic Leukemia Research (19 papers), Systemic Sclerosis and Related Diseases (18 papers) and Biosimilars and Bioanalytical Methods (10 papers). The work is most often cited by research in Rheumatology (7.1k citations), Hematology (2.0k citations), Immunology (3.5k citations), Pathology and Forensic Medicine (1.3k citations) and Dermatology (635 citations). Peter Nash has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Dafna D. Gladman, Daniel O. Clegg, Philip Mease, Christian Antoni, Philip J. Mease, Désirée van der Heijde, Luminita Pricop, Iain B. McInnes, Frank Behrens and Paul Emery. Their work appears in journals such as Annals of the Rheumatic Diseases, Rheumatology and Therapy, Lara D. Veeken, RMD Open and The Journal of Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.